This review outlines the accomplishments and potential developments of targeted alpha (α)
particle therapy (TAT). It discusses the therapeutic advantages of the short and highly …

As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

Conspectus “Theranostics” is a portmanteau that links the fields of therapeutics and
diagnostics; it describes a personalized medical approach with the expectation to improve …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

At present, prostate cancer remains the second most occurring cancer in men, in Europe.
Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as
a result of the growing research interest in personalized medicine to improve diagnostic …

Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using …

The intense accumulation of prostate-specific membrane antigen (PSMA) radioligands in
salivary glands is still not well understood. It is of concern for therapeutic applications of …

Introduction Targeted alpha-radiation therapy (TAT) with 225 Ac-labeled prostate-specific
membrane antigen (PSMA) ligands is a promising novel treatment option for metastatic …